DCM
TGTX icon

Dupont Capital Management’s TG Therapeutics TGTX Stock Holding History

Dupont Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-18,889
Closed -$223K – 1179
2022
Q4 		$223K Sell
18,889
-2,025
-10% -$14.7K 0.01% 760
2022
Q3 		$124K Buy
+20,914
New +$137K 0.01% 976
2018
Q3 		– Sell
-47,454
Closed -$624K – 1031
2018
Q2 		$624K Sell
47,454
-10,967
-19% -$151K 0.01% 659
2018
Q1 		$830K Sell
58,421
-6,536
-10% -$83.5K 0.02% 565
2017
Q4 		$533K Buy
64,957
+39,295
+153% +$343K 0.01% 647
2017
Q3 		$304K Hold
25,662
– – 0.01% 760
2017
Q2 		$258K Buy
+25,662
New +$287K 0.01% 787

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dupont Capital Management's TGTX Position: Q1 2023 in Review

Dupont Capital Management sold out of TG Therapeutics (TGTX) in Q1 2023, closing a stake of 18,889 shares — an estimated $223K sold.

Dupont Capital Management first reported a position in TGTX in Q2 2017 and held it in 7 quarters. The position peaked at $830K in Q1 2018. 214 funds tracked by Wall St. Rank hold TGTX as of Q1 2023.

  • Dupont Capital Management reported no remaining TG Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Dupont Capital Management sold 18,889 TG Therapeutics shares in Q1 2023, an estimated $223K.
  • Dupont Capital Management first reported a position in TG Therapeutics in Q2 2017 and held it in 7 quarters.
  • Dupont Capital Management's TG Therapeutics position peaked at $830K in Q1 2018.
  • 214 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2023.

Based on Dupont Capital Management's 13F filing for Q1 2023, filed 28 Apr 2023.